‘MEGA dPCR reveals chromosomal aberrations, NHEJ precise repair, recurrent nuclease cleavage and DSB half-life”

Giandomenico Turchiano is Associate Director, gene therapy safety, in AstraZeneca; Honorary group leader at the Great Ormond Street Hospital, University College London and Contract Professor at the Federico II University of Naples. His work aims at developing novel and safer therapeutic approaches for genetic diseases. He is a pioneer in the genomic stability characterization after gene editing describing and quantifying novel DNA repair features.

Giandomenico recently created and developed the clinical grade MEGA dPCR and CAST-seq technologies for the mutations assessment after designer nuclease treatment on primary cells.

His work characterised the activity of gene therapy tools such as transposons and CRISPR/Cas nucleases in primary human keratinocytes, T-cells and hematopoietic stem and progenitor cells providing information for Investigational New Drugs applications.